725 related articles for article (PubMed ID: 8630906)
1. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
3. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction.
Stewart-Akers AM; Cairns JS; Tweardy DJ; McCarthy SA
Blood; 1993 May; 81(10):2671-8. PubMed ID: 8490177
[TBL] [Abstract][Full Text] [Related]
4. Coinduction of granulocyte-macrophage colony-stimulating factor release and lymphokine-activated killer cell susceptibility in monocytes by interleukin-2 via interleukin-2 receptor beta.
Epling-Burnette PK; Wei S; Blanchard DK; Spranzi E; Djeu JY
Blood; 1993 Jun; 81(11):3130-7. PubMed ID: 8499646
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes.
Singh SM; Sone S; Inamura N; Ogura T
Int J Cancer; 1989 Jul; 44(1):170-6. PubMed ID: 2663733
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte/macrophage-colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients.
Takahashi K; Saito S; Kamamura Y; Katakawa M; Monden Y
Cancer Immunol Immunother; 2000 Dec; 49(10):537-43. PubMed ID: 11129324
[TBL] [Abstract][Full Text] [Related]
7. The effects of recombinant human granulocyte-macrophage colony-stimulating factor on the induction of lymphokine-activated killer cells in vitro.
Okamura S; Tanaka T; Yamaga S; Omori F; Niho Y
Int J Immunopharmacol; 1991; 13(5):587-93. PubMed ID: 1783473
[TBL] [Abstract][Full Text] [Related]
8. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2.
Horton SA; Oldham RK; Yannelli JR
Cancer Res; 1990 Mar; 50(6):1686-92. PubMed ID: 2306722
[TBL] [Abstract][Full Text] [Related]
9. Killing of alveolar macrophages and of monocytes that have responded to granulocyte-macrophage colony-stimulating factor by human lymphokine-activated killer cells.
Sone S; Inamura N; Singh SM; Okubo A; Yanagawa H; Nakanishi M; Ogura T
Jpn J Cancer Res; 1989 Jul; 80(7):662-9. PubMed ID: 2507489
[TBL] [Abstract][Full Text] [Related]
10. Suppression of human monocyte function against Candida albicans by autologous IL-2-induced lymphokine-activated killer cells.
Wei S; Serbousek D; McMillen S; Blanchard DK; Djeu JY
J Immunol; 1991 Jan; 146(1):337-42. PubMed ID: 1898605
[TBL] [Abstract][Full Text] [Related]
11. Lymphokine-activated killer cell regulation of T-cell-mediated immunity to Candida albicans.
Wei S; Blanchard DK; McMillen S; Djeu JY
Infect Immun; 1992 Sep; 60(9):3586-95. PubMed ID: 1500166
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of neuronal cells by culture supernatant of T lymphocytes triggered by anti-CD3 mAb followed by propagation in the presence of interleukin-2.
Ishiguro M; Okada A; Asai K; Kojima K; Okada H
Microbiol Immunol; 2016 Jan; 60(1):47-55. PubMed ID: 26616436
[TBL] [Abstract][Full Text] [Related]
13. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
Provinciali M; Di Stefano G; Stronati S; Fabris N
Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
[TBL] [Abstract][Full Text] [Related]
14. Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Ohno T
J Hematother; 1999 Feb; 8(1):29-37. PubMed ID: 10192299
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion.
Takahashi K; Sone S; Saito S; Kamamura Y; Uyama T; Ogura T; Monden Y
Jpn J Cancer Res; 1995 Sep; 86(9):861-6. PubMed ID: 7591964
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses.
Baxevanis CN; Tsavaris NB; Papadhimitriou SI; Zarkadis IK; Papadopoulos NG; Bastounis EA; Papamichail M
Eur J Cancer; 1997 Jul; 33(8):1202-8. PubMed ID: 9301443
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).
Masucci G; Ragnhammar P; Wersäll P; Mellstedt H
Cancer Immunol Immunother; 1990; 31(4):231-5. PubMed ID: 2199042
[TBL] [Abstract][Full Text] [Related]
19. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
20. TNF-alpha and IFN-gamma reverse IL-4 inhibition of lymphokine-activated killer cell function.
Swisher SG; Economou JS; Holmes EC; Golub SH
Cell Immunol; 1990 Jul; 128(2):450-61. PubMed ID: 2113430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
